Thanks @Bunter62,
The unknown of course is weather or not its a BP who may be interested or multiple BPs. There have been multiple failed clinical trials, I found 10 without any effort, [see below] 3 of them big Pharma so the interest is there. On this basis I think it fair to assume we should have multiple interested parties.
The other thing is, we have discussed the benefit on this forum of having a ODD and without a doubt it is a big deal. But the FDA advising accelerated approval is a possibility has possibly slipped under the radar. If approved after the Adaptive 2/3 trial, it means MPL could be on the market 12 months earlier. And unbelievably it could be a billion dollar drug in that first full year or shortly after.
The fact that these companies have already conducted trials also tells us a lot of their market research has already been done.
My Target is A$ 2-3 per share but that is just what will make very very very comfortable and not based on anything of substance.
1. Ceftriaxone in ALS Study (CAALS) - No specific company sponsor
2. NP001 Phase 2 trial - Neuraltus Pharmaceuticals
3. Mexiletine Phase 3 trial - Biohaven Pharmaceuticals
4. Olesoxime in ALS Phase 3 trial - Roche
5. NP001 Phase 3 trial - Neuraltus Pharmaceuticals
6. Arimoclomol in ALS Phase 2/3 trial - CytRx Corporation
7. Biogen's dexpramipexole Phase 3 trial - Biogen
8. Brainstorm Cell Therapeutics Phase 3 trial of NurOwn - BrainStorm Cell Therapeutics
9. Gilenya (fingolimod) Phase 2 trial in ALS - Novartis
10. Tirasemtiv Phase 2b trial - Cytokinetics
Cheers
- Forums
- ASX - By Stock
- PAA
- Ann: Application for quotation of securities - PAA
Ann: Application for quotation of securities - PAA, page-55
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
22.0¢ |
Change
0.015(7.32%) |
Mkt cap ! $97.90M |
Open | High | Low | Value | Volume |
21.5¢ | 23.0¢ | 21.5¢ | $443.1K | 2.052M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 120200 | 21.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.0¢ | 124358 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 120200 | 0.215 |
5 | 281446 | 0.210 |
5 | 324206 | 0.205 |
12 | 449445 | 0.200 |
8 | 267463 | 0.195 |
Price($) | Vol. | No. |
---|---|---|
0.220 | 124358 | 3 |
0.225 | 23500 | 2 |
0.230 | 166203 | 4 |
0.240 | 159752 | 3 |
0.245 | 196127 | 3 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online